GlassScriptPhysician profile
Beverly J Anarumo
NPI 1740341700
$2,141.67
in general payments reported to CMS, 2019-2025
24 companies · $70.73 in 2025
The $70.73 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $235 · 2021: $225 · 2022: $367 · 2023: $225 · 2024: $269 · 2025: $70.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $362.77 | 2019-2023 | |
| Tris Pharma INC | $284.25 | 2019-2024 | Onyda Xr |
| Ironshore Pharmaceuticals INC. | $229.82 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.77 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $174.96 | 2022-2024 | Qelbree |
| Nevro Corp. | $146.30 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Rexulti |
| Phadia US INC. | $76.28 | 2022-2025 | Immunocap |
| Genentech USA, INC. | $75.54 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $67.79 | 2024 | Ycanth |
| Corium, LLC | $65.15 | 2021-2023 | Azstarys |
| Sanofi Pasteur INC. | $44.80 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $42.15 | 2019 | |
| Collegium Pharmaceutical, INC. | $40.74 | 2025 | Jornay Pm |
| Exeltis, USA INC. | $33.81 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.89 | 2022 | |
| Dermira, INC. | $23.01 | 2020 | |
| Sobi, INC | $22.94 | 2019 | |
| Alk-Abello, INC | $21.53 | 2023 | Ragwitek, Odactra, Grastek |
| Rhodes Pharmaceuticals L.P. | $17.80 | 2019 | |
| Cranial Technologies, INC | $15.96 | 2022 | |
| Abbvie INC. | $15.94 | 2020 | |
| Neurelis, INC. | $15.00 | 2021 | |
| Cipher Pharmaceuticals US LLC | $14.48 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Anarumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.